Published in Cancer Weekly, October 11th, 2005
Study 1: Scientists have developed a method for anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells.
"The residual tumor cells remaining after completion of standard chemotherapy and radiation treatment in B lymphoma patients may be eradicated by active immunotherapy that stimulates tumor-specific T lymphocytes. Irradiated autologous lymphoma cells expressing tumor-associated antigens (TAA) may serve as a potential tumor vaccine, provided that they are effectively targeted to the antigen-presenting cells (APC)," investigators...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.